Article
Novartis says no liver toxicity seen so far its BTK inhibitor
Rating:
0.0
Views:
70
Likes:
1
Library:
1
Novartis said no signs of liver damage had been seen in trials testing its anti-inflammatory drug candidate remibrutinib so far, voicing cautious optimism that it could elude the side effects that have beset rival products in the same drug class.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value